Your browser doesn't support javascript.
loading
Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD.
Seddighi, Sahba; Qi, Yue A; Brown, Anna-Leigh; Wilkins, Oscar G; Bereda, Colleen; Belair, Cedric; Zhang, Yongjie; Prudencio, Mercedes; Keuss, Matthew J; Khandeshi, Aditya; Pickles, Sarah; Hill, Sarah E; Hawrot, James; Ramos, Daniel M; Yuan, Hebao; Roberts, Jessica; Kelmer Sacramento, Erika; Shah, Syed I; Nalls, Mike A; Colon-Mercado, Jenn; Reyes, Joel F; Ryan, Veronica H; Nelson, Matthew P; Cook, Casey; Li, Ziyi; Screven, Laurel; Kwan, Justin Y; Shantaraman, Anantharaman; Ping, Lingyan; Koike, Yuka; Oskarsson, Björn; Staff, Nathan; Duong, Duc M; Ahmed, Aisha; Secrier, Maria; Ule, Jerneg; Jacobson, Steven; Rohrer, Jonathan; Malaspina, Andrea; Glass, Jonathan D; Ori, Alessandro; Seyfried, Nicholas T; Maragkakis, Manolis; Petrucelli, Leonard; Fratta, Pietro; Ward, Michael E.
Afiliação
  • Seddighi S; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Qi YA; Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Brown AL; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Wilkins OG; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Bereda C; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Belair C; The Francis Crick Institute, London, UK.
  • Zhang Y; Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Prudencio M; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Keuss MJ; Laboratory of Genetics and Genomics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Khandeshi A; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Pickles S; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Hill SE; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Hawrot J; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Ramos DM; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Yuan H; Laboratory of Genetics and Genomics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Roberts J; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Kelmer Sacramento E; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Shah SI; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Nalls MA; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Colon-Mercado J; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Reyes JF; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Ryan VH; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Nelson MP; Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Jena, Germany.
  • Cook C; Data Tecnica International, Washington, DC, USA.
  • Li Z; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Screven L; Data Tecnica International, Washington, DC, USA.
  • Kwan JY; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Shantaraman A; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Ping L; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Koike Y; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Oskarsson B; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Staff N; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Duong DM; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Ahmed A; Data Tecnica International, Washington, DC, USA.
  • Secrier M; Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA.
  • Ule J; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
  • Jacobson S; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Rohrer J; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Malaspina A; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Glass JD; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Ori A; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Seyfried NT; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Maragkakis M; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Petrucelli L; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Fratta P; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Ward ME; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
bioRxiv ; 2023 Jan 23.
Article em En | MEDLINE | ID: mdl-36747793
Functional loss of TDP-43, an RNA-binding protein genetically and pathologically linked to ALS and FTD, leads to inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. However, the possibility of de novo protein synthesis from cryptic exon transcripts has not been explored. Here, we show that mRNA transcripts harboring cryptic exons generate de novo proteins both in TDP-43 deficient cellular models and in disease. Using coordinated transcriptomic and proteomic studies of TDP-43 depleted iPSC-derived neurons, we identified numerous peptides that mapped to cryptic exons. Cryptic exons identified in iPSC models were highly predictive of cryptic exons expressed in brains of patients with TDP-43 proteinopathy, including cryptic transcripts that generated de novo proteins. We discovered that inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Finally, we showed that these de novo peptides were present in CSF from patients with ALS. The demonstration of cryptic exon translation suggests new mechanisms for ALS pathophysiology downstream of TDP-43 dysfunction and may provide a strategy for novel biomarker development.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: BioRxiv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: BioRxiv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos